The First 1000 Dendritic Cell Vaccinees

References

• Holtl L., Rieser C., Papesh C., Ramoner R., Herold M., Klocker H., Radmayr C., Stenzl A., Bartsch G., Thurner M. Cellular and immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 1999; 161: 777–782
   PubMed Web of Science ®Google Scholar
• Steinman R. M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001; 94: 459–473
   PubMed Web of Science ®Google Scholar
• Mukherji B., Chakraborty N. G., Yamasaki S., Okina T., Yamase H., Sporn J. R., Kurtzman M. T., Ergin M. T., Ozols J., Meehan J., Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. 1995; 9: 8078–8082
   Google Scholar
• Toungouz M., Libin M., Bulte F., Faid L., Lehmann F., Duriau D., Laporte M., Gangji D., Bruyns C., Lambermont M., Goldman M., Velu T. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukoc. Biol. 2001; 69: 937–943
   PubMed Web of Science ®Google Scholar
• Desai J., Mitchell P., Lovelan B., Bardsley B., White S., Zhao A., Apostolopoulos V., Oslinski C., Xing P. X., Smith C., McDonald C., McKenzie I. A phase I trial of dendritic cells pulsed with MUC1 peptide in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2002; 21: 15b, (abstr)
   Google Scholar
• Nair S. K., Morse M., Boczkowski M. A., Cumming I., Vasovic L., Gilboa E., Lyerly K. Induction of tumor-specific cytotoxic t lymphycytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 2002; 35: 540–549
   Google Scholar
• Nishiyama T., Tachibana M., Horiguchi Y., Nakamura K., Ikeda Y., Takesako K., Murai M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res. 2001; 7: 23–31
   PubMedGoogle Scholar
• Brossart P., Wirths S., Stuhler G., Reichardt V. L., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2001; 96: 3102–3108
   Web of Science ®Google Scholar
• Morse M. A., Mosca P. J., Hobeika A., Clay T., Fisher M., Peter St. M., Williams R., Cumming R. I., Caron D., Lyerly H. K. Immunotherapy with Flt3-ligand (Flt3L) mobilized dendritic cells (DC) loaded with carcinoembryonic antigen (CEA) peptide (CAP-1) in patients with metastatic malignancies expressing CEA. Proc. Am. Soc. Clin. Oncol. 2000; 19: 469a, (abstr)
   Google Scholar
• Vonderheide R. H., Domchek S. M., Hahn W. C., George D. J., Stephans K. F., Schultze J. L., Nadler L. M. Vaccination of cancer patients against telomerase: a phase I study using peptide-pulsed dendritic cells. Blood 2001; 98: 508a, (abstr)
   Web of Science ®Google Scholar
• Nussey F. E., Downing I., Waterfall M., Campbell J., Hunter N. R., Parker J., Innes J., Samuel K., Cook G., Turner M. L., Leonard R. C. A phase one trial of autologous MUC-1 pulsed dendritic cells for the treatment of patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 476a, (abstr)
   Google Scholar
• Clay T. M., Hobeika A. C., Colling K., Ghanayem M., Heck R., Peplinski S., Peter St.M., Cheever M. A., Grabstein K., Mosca P. J., Morse M. A., Lyerly K. Comparison of the immunologic responses in metastatic breast cancer patients vaccinated with either non-matured or matured dendritic cells loaded with HER-2/neu intracellular domain (ICD) protein. Proc. Am. Assoc. Cancer Res. 2002; 43: 89, (abstr)
   Google Scholar
• Aoyama T., Fujii Y., Hasumi K., Yamaguchi S., Terai M., Yasuda R., Arai T., Nathan F. E., Mastrangelo M. J., Sato T. Active specific immunotherapy with tumor-antigen pulsed dendritic cells (DC) and CD-40 ligand expressing activated T cells (AT). Proc. Am. Soc. Clin. Oncol. 2001; 20: 221b, (abstr)
   Google Scholar
• Cajal R., Maordomo J. I., Yubero A., Lasierra P., Isla D., Blasco C., Fuertes M. A., Palomera R., Sousa R., Guermes A., Escudero P., Saenz A., Garcia M., Larrad L., Tres A. Immunological and clinical effects of immunotherapy with dendritic cells pulsed with tumor lysates in patients with advanced cancer. A pilot trial. Proc. Am. Soc. Clin. Oncol. 2000; 19: 454a, (abstr)
   Google Scholar
• Chang A. E., Redman B. G., Whitfield J. R., Nickoloff B. J., Braun T. M., Lee P. P., Geiger J. D., Mule J. J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002; 8: 1021–1032
   PubMed Web of Science ®Google Scholar
• Avigan D., Gong J., Uhl L., Wu Z., Vasir D., Smith T., Borges V., Atkins M., Stone C., Giallombardo N., Schadt K., Tetreault J. C., Kufe D. Dendritic cell tumor fusions as a novel tumor vaccine: a phase I trial for patients with metastatic breast cancer. Blood 2001; 98: 14a, (abstr)
   Web of Science ®Google Scholar
• Morse M. A., Coleman R. E., Akabani G., Niehaus N., Coleman D., Lyerly H. K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999; 59: 56–58
   PubMed Web of Science ®Google Scholar
• Fong L., Hou Y., Benike C., Yuen A., Fisher G. A., Davis M. M., Engleman E. C. Vaccination with increasing doses of Flt3 ligand expanded dendritic cells loaded with a carcinoembyonic antigen derived epitope. Proc. Am. Assoc. Cancer Res. 2002; 43: 143–144, (abstr)
   Google Scholar
• Westermann J., Kopp J., Korner I., Dohner C., Dohner H., Mohm J., Ehninger G., Richter G., Dorken B., Pezzutto A. Dendritic cells for vaccination in BCR/ABL-positive chronic myeloid leukemia. Blood 2000; 96: 144a, (abstr)
   Web of Science ®Google Scholar
• Westermann J., Kopp J., Korner I., Dohner C., Dohner H., Dorken B., Pezzutto A. Dendritic cells as vaccine in BCR/ABL-positive chronic myelogenous leukemia: a phase I study. Blood 2001; 98: 350a, (abstr)
   Web of Science ®Google Scholar
• Ossenkeppele G. J., Stam A. G.M., Westers T. M., de Gruijl T. D., van de Loosdrecht A. A., Scheper R. J. Pilot study on active specific immunization with autologous in vitro cultured leukemic dendritic cells in chronic phase CML. Blood 2001; 98: 265b, (abstr)
   Web of Science ®Google Scholar
• Fong L., Hou Y., Benike C., Wu L., Engleman E. G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Assoc. Sci. 2001; 98: 8809–8814
   PubMed Web of Science ®Google Scholar
• Weihrauch M. R., Geisen C., Jurkeiwicz E., Wittig B., Diehl V., Wolf J., Bohlen H. Combined immuno-/chemotherapy with CAP-1 pulsed dendritic cells or CPG-ODN in patients with primary metastatic colon cancer. Blood 2000; 96: 618a, (abstr)
   PubMed Web of Science ®Google Scholar
• Sandanaga N., Nagashima H., Mashino K., Tahara K., Yamaguchi H., Ohta M., Fujii T., Tanaka F., Inoue H., Takesako K., Akiyoshi T., Mori M. Dendritic cell vaccination with mage peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 2001; 7: 2277–2284
   PubMed Web of Science ®Google Scholar
• Tsunoda T., Tanimura H., Tanaka H., Matsuda K., Umano Y., Shono Y., Iwahashi M., Yamaue H., Takesako K., Ideno M., Nukaya I. Cytotoxic peptide can elicit HLA-restricted CEA specific CTL from colorectal cancer patients in vivo —development of colorectal cancer vaccine. Proc. Am. Assoc. Cancer Res. 1999; 40: 310, (abstr)
   Google Scholar
• Itoh T., Ueda Y., Kawashima I., Nukaya I., Fujiwara H., Fuji N., Yamashita T., Yoshimura T., Okugawa K., Iwasaki T., Ideno M., Takesako K., Mitsihashi M., Orita K., Yamagishi H. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol. Immunother. 2002; 51: 99–106
   PubMed Web of Science ®Google Scholar
• Rains N., Cannan R. J., Chen W., Stubbs R. S. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001; 48: 347–351
   PubMed Web of Science ®Google Scholar
• Abe T., Takahashi M., Aichun L., Narita T., Furukawa T., Toba K., Aizawa Y. Application of dendritic cells pulsed with SART-1 peptide to patients with esophageal cancer. Blood 2000; 96: 38b, (abstr)
   Web of Science ®Google Scholar
• Takahashi M., Narita M., Abe T., Liu A., Kanda T., Kaifu T., Yamanaka R., Furukawa T., Toba K., Hatakeyama K., Tanaka R., Aizawa Y. Anti-tumor immunotherapy using dendritic cells pulsed with tumor peptides or acid-eluted tumor antigens. Blood 2001; 98: 40b, (abstr)
   Web of Science ®Google Scholar
• Tanigawa K., Shimizu K., Aruga A., Takasaki K. A clinical trial of intratumoral injection of dendritic cells to GI cancers. Proc. Am. Assoc. Cancer Res. 2001; 42: 27, (abstr)
   Google Scholar
• Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Riedinger M. S., Zhang W., Prins R. M., Black K. L. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001; 61: 842–847
   PubMed Web of Science ®Google Scholar
• Chuhjo T., Wang H., Kondo Y., Uchiyama N., Hayashi Y., Fujii S., Yamashita S., Nakao S. Dendritic cell therapy of glioblastoma: evidence of antitumor immune response in vivo. Blood 2000; 96: 617a, (abstr)
   Web of Science ®Google Scholar
• Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Lee P. K., Incardona F., Yong W. H., Thompson R. C., Riedinger M. S., Black K. L. Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma. Proc. Am. Assoc. Cancer Res. 2001; 42: 274–275, (abstr)
   Google Scholar
• Liau L. M., Salgaller M. L., Kiertscher S. M., Cloughesy T. F., Mischel P. S., Martin N. A., Becker D. P., Roth M. D. Dendritic cell vaccine presenting eluted antigens for treatment of patients with glioblastoma multiforme: interim phase I trial results of DCVax™-Brain(elu). Proc. Am. Assoc. Cancer Res. 2002; 43: LB130, (abstr)
   Google Scholar
• Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 2001; 50: 337–344
   PubMed Web of Science ®Google Scholar
• Park T. W., Hernando J. J., Kuebler K., Bauknecht T. A phase I study of vaccination with tumor cell lysate-pulsed dendritic cells in patients with advanced gynecologic cancers. Proc. Am. Soc. Clin. Oncol. 2001; 20: 269a, (abstr)
   Google Scholar
• Stift A., Dubsky P., Friedt J. P., Bachleitner T., Schueller G., Tadlbauer K., Jakesz R., Gnant M. F. A pilot study for a phase I trial of active immunotherapy using tumor lysate pulsed autologous dendritic cells in patients with incurable malignancies. Proc. Am. Soc. Clin. Oncol. 2000; 19: 464a, (abstr)
   Google Scholar
• Midgley R., Kerr D. J., Mirza N., Milner A., Hodgkin E., Barker S., Adams D. A phase II dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC). Proc. Am. Soc. Clin. Oncol. 2002; 21: 23b, (abstr)
   Google Scholar
• Hsu F. J., Benike C., Fagnoni F., Liles T. M., Czerwinski D., Taidi B., Engleman E. G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996; 2: 52–58
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Komarovskaya M., Song B., Doyon A. G. Active immunotherapy of patients with lymphoma with sequential dendritic cell and protein/adjuvant idiotype vaccines. Blood 1999; 94: 386a, (abstr)
   Web of Science ®Google Scholar
• Hsu F. J., Komarovskaya M., Song B., Doyon A. G. A clinical trial of sequential dendritic cell and protein/adjuvant idiotype vaccines in patients with follicular lymphomas. Blood 2001; 98: 466a–467a, (abstr)
   Web of Science ®Google Scholar
• Timmerman J. M., Czerwinski D. K., Davis T. A., Hsu F. J., Benike C., Hao Z. M., Taidi B., Ranjani R., Caspar C. B., Okada C. Y., van Beckhoven A., Liles T. M., Engleman E. G., Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immunological responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Fay J., Palucka K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Bhardwaj N., Pineiro L., Stone M., Steinman R., Banchereau J. Dendritic cell immunotherapy of metastatic melanoma using CD34 + hematopoietic progenitor-derived dendritic cells (CD34-DC) induced immune responses to melanoma antigen and resulted in clinical regression of metastatic disease. Blood 2000; 96: 807a, (abstr)
   Web of Science ®Google Scholar
• Lau R., Kuniyoshi J., Jeffery G., Marty V., Snively J., Groshen S., Weber J. Phase II trial of CD40 ligand treated peptide-pulsed dendritic cells plus IL-2 in advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2001; 20: 264a, (abstr)
   Google Scholar
• Leong S. P.L., Zhou Y. M., Peng M., Nelken P., Chang J. W.C., Vaquerano J. E., Hyun W. C. Immunotherapy of melanoma with dendritic cells pulsed with autologous melanoma apoptotic bodies. Proc. Am. Soc. Clin. Oncol. 2001; 20: 268a, (abstr)
   Google Scholar
• Lotze M. T., Shurin M., Esche C., Tahara H., Storkus W., Kirkwood J. M., Whiteside T. L., Elder E. M., Okada H., Robbins P. Interluekin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J. Sci. Am. 2000; 6(Suppl 1)S61–S66
   PubMedGoogle Scholar
• Mackensen A., Herbst B., Chen J. L., Kohler G., Noppen C., Herr W., Spagnoli G. C., Cerundolo V., Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 2000; 86: 385–392
   PubMed Web of Science ®Google Scholar
• Nestle F. O., Alijagic S., Gilliet M., Sun Y., Drrabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cels. Nat. Med. 1998; 4: 328–332
   PubMed Web of Science ®Google Scholar
• Nestle F. O. Dendritic cell vaccination for cancer therapy. Oncogene 2000; 19: 6673–6679
   PubMed Web of Science ®Google Scholar
• Panelli M. C., Wunderlich J., Jeffries J., Wang E., Mixon A., Rosenberg S. A., Marincola F. M. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 2000; 23: 487–498
   PubMed Web of Science ®Google Scholar
• Ribas A., Butterfield L. H., Vu H. T., Amarnani S., Dissette V. N., Oseguera D. K., McBride W. H., Glaspy J. A., Economos J. S. Dose and route of dendritic cell (DC)-based vaccination for further human testing: a phase I trial. Proc. Am. Soc. Clin. Oncol. 2001; 20: 268a, (abstr)
   Google Scholar
• Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E. B., Steinman R. M., Enk A., Kampgen E., Schuler G. Vaccination with mage-3A1, peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999; 190: 1669–1678
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B., Dieckmann D., Keikavoussi P., Bender A., Maczek C., Jonuleit H., Roder C., Haendle I., Leisgang W., Dunbar R., Cerundolo V., von Den Driesch P., Knop J., Brocker E. B., Enk A., Kampgen E., Schuler G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 2000; 154: 3492–3496
   Google Scholar
• Banchereau J., Palucka A. K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K. M., Bhardwaj N., Pineiro L., Steinman R., Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34 + progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61: 6451–6458
   PubMed Web of Science ®Google Scholar
• Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T. B., Paragnik L., Kandemir A., Lee P. P., Schuler G., Knop J., Enk A. H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 2001; 93: 243–251
   PubMed Web of Science ®Google Scholar
• Gajewski T. F., Fallarino F., Ashikari A., Sherman M. Immunization of HLA-A2 + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 2001; 3(Suppl 3)895s–901s
   Google Scholar
• Riccobon A., Ridolfi R., De Paola F., Barzanti F., Mosconi G., Ortolani F., Stefanelli M., Ibrahim T., Ridolfi L., Fabbri M., Flamini E., Amadori D. Vaccination with dendritic cells (DC) pulsed with heat shock proteins (HSP) or lysate from autologous tumor in advanced melanoma patients. Proc. Am. Soc. Clin. Oncol. 2000; 19: 469a, (abstr)
   Google Scholar
• Linette G., Jonasch E., Longerich S., Yang D. S., Webb I., Szczepiorkowski Z., Cheung A., Haluska F. Phase I study of therapy with peptide-pulsed autologous dendritic cells for advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2000; 19: 467a, (abstr)
   Google Scholar
• Faries M. B., Bedrosian I., Xu S., Kohl K., Nissenbaum H., Cohen P., Czerniecki B. J. Effective immunization to melanoma antigens by intranodal injection of mature, CD83 + dendritic cells. Proc. Am. Soc. Clin. Oncol. 2000; 19: 453a, (abstr)
   Google Scholar
• Punt C. J.A., de Vries I. J.M., Eggert A. A.O., Schreurs M. W.J., Scharenborg N. H., Verstratenm H. G.G., Ruiter D. J., Boerman O. C., Oyen W. J.G., Adema G. J., Figdor C. G. Immunization with dendritic cells (DC) pulsed with synthetic peptides, murine and clinical studies. Proc. Am. Assoc. Cancer Res. 1999; 40: 312, (abstr)
   Google Scholar
• Schuler-Thurner B., Schultz E. S., Berger T. G., Weinlich G., Ebner S., Woerl P., Bender P., Feuerstein B., Fritsch P. O., Romani N., Schuler G. Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. Exp. Med. 2002; 19: 1279–1288
   Google Scholar
• Nagayama H., Sato K., Enomoto M., Uchimaru K., Saida T., Shimada S., Kawakami Y., Asano S., Yamashita N., Takahashi T. A. Phase I clinical study of autologous monocyte-derived dendritic cell therapy for stage IV malignant melanoma patients in Japan. Blood 2000; 96: 323b, (abstr)
   Web of Science ®Google Scholar
• Morishita M., Oyaizu N., Uchimaru K., Sato K., Nagayama H., Inzazwa T., Nakoako T., Akagawa E., Shimada S., Kawakami Y., Saida T., Yamamoto A., Tani K., Asana S., Takahashi T., Yamashita N. Dendritic cell therapy for stage IV melanoma: two cases of multiple tumor necrosis. Blood 2001; 98: 18a–19a, (abstr)
   Web of Science ®Google Scholar
• Chakraborty N. G., Sporn J. R., Tortora A. F., Kurtzman S. H., Yamase H., Ergin M. T., Mukherji B. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 1998; 47: 58–64
   PubMed Web of Science ®Google Scholar
• Bercovici N., Massicard S., Baron V., Pauillac F., Hamon I., Agrawal S., Goxe B., Latour N., Duffour M.-T., Boccaccio C., Boyer A., Nardin A., Chauvet I., Prigent D., Heshmati F., Duriau D., Vereecken P., Bruyns C., Lehmann F., Velu T., Romet-Lemonne J.-L., Abastado J.-P., Salcedo M. Immunization with dendritic cells generated in the presence of GM-CSF and IL-13 loaded with an allogeneic melanoma cell lysate: a phase I study in patients with metastatic melanoma. Proc. Am. Assoc. Cancer Res. 2002; 43: 558–559, (abstr)
   Google Scholar
• Chang J. W., Hsieh J.-J., Chen J.-S., Yang T.-S., Wang C.-H., Chiang H.-F., Lo Y.-F., Chang C.-J., Yang C.-S., Yeh J.-T., Chang T.-C., Chen Y.-R., Liao S.-K., Gung C. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma. Proc. Am. Soc. Clin. Oncol. 2002; 21: 3b, (abstr)
   Google Scholar
• Wallack M. K., Kim E. M., Stavropoulos C. I., Mancke B., Sivanandham M. A pilot trial with a vaccinia virus-augmented melanoma lysate-pulsed dendritic cell vaccine (DC-Melvac) for patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2002; 21: 240b, (abstr)
   Google Scholar
• Tozer R. G., McCulloch P. B., Dent P., Levine M., Ross C., Scheid E., Gauldie J., Kowalski Y., Wan B., Roberts R. Vaccination with autologous CD34 + derived dendritic cells transduced with an adenovirus expressing human gp100 in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 2002; 21: 352a, (abstr)
   Google Scholar
• Haluska F. G., Linette G. P., Jonasch E., Hodi S., Longerich S., Yang S., Webb I., Stowell C., Kaplan J., Roberts B., Goldberg M. Immunologic gene therapy of melanoma: phase I study of therapy with autologous dendritic cells transduced with recombinant adenoviruses encoding melanoma antigens. Proc. Am. Soc. Clin. Oncol. 2000; 19: 453a, (abstr)
   Google Scholar
• Cull G., Durant L., Haynes A., Russell N. Generation of idiotype-specific immune responses following vaccination with autologous paraprotein pulsed dendritic cells in myeloma. Blood 2000; 92: 275b, (abstr)
   Web of Science ®Google Scholar
• Lacy M. Q., Wettstein P., Gertz M. A., Gastineau D. A., Greipp P. R., Fonseca R., Lust J., Witzig T., Rajkumar S. V., Valone F., Kyle R. A. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma. Blood 2000; 96: 374a, (abstr)
   Web of Science ®Google Scholar
• Lim S. H., Bailey-Wood R. Idiotype protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 1999; 83: 215–222
   PubMed Web of Science ®Google Scholar
• Liso A., Stockerl-Goldstein K. E., Aufferman S., Benike C. J., Reichardt V., van Beckhoven A., Rajapaksa R., Engleman E. G., Blume K. G., Levy R. Idiotype vaccination using dendritic cells afer autologous peripheral blood progenitor cell transplantation for multiple myeloma. Blood 1999; 94: 715a, (abstr)
   Web of Science ®Google Scholar
• MacKenzie M., Peshwa M. V., Wun T., Wolf J., Mason J., Caggiano V., Redfern C., Strang G., Valone F. Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). Blood 2000; 96: 166a, (abstr)
   Web of Science ®Google Scholar
• Titzer S., Christensen O., Manzke O., Tesch H., Wolf J., Emmerich B., Carsten C., Diehl V., Bohlen H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Brit. J. Haematol. 2000; 108: 805–816
   PubMed Web of Science ®Google Scholar
• Maecker H. T., Auffermann-Gretzinger S., Nomura L. E., Liso A., Czerwinski D. K., Levy R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res. 2001; 7(Suppl 3)902s–908s
   PubMed Web of Science ®Google Scholar
• Reichardt V. L., Wirths S., Milazzo C., Brossart P., Stuhler G., Einsele H., Brugger W., Kanz L. Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells. Blood 2000; 96: 63a, (abstr)
   PubMedGoogle Scholar
• Reichardt V. L., Milazzo C., Brugger W., Einsele H., Kanz L., Brossart P. Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells. Blood 2001; 98: 378a–379a, (abstr)
   Web of Science ®Google Scholar
• Wen Y. J., Ling M., Bailey-Wood R., Lim S. H. Idiotype protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 1998; 4: 957–962
   PubMed Web of Science ®Google Scholar
• Ishisaka T., Nevin B., Valone F. H., Kothari S. S., Peshwa M. V. Comparison of cryopreserved versus fresh formulation of idiotype-loaded autologous dendritic cell vaccine. Blood 2001; 98: 309b, (abstr)
   Web of Science ®Google Scholar
• Yi Q., Desikan R., Barlogie B., Munsh N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Blood 2001; 98: 374a, (abstr)
   PubMed Web of Science ®Google Scholar
• Lacy M., Wettstein P., Gertz M. A., Gastineau D. A., Greipp P. R., Fonseca R., Dispenzieri A., Lust J., Witzig T., Rajkumar S. V., Geyer S., Valone F., Kyle R. A. Postautologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020). Proc. Am. Soc. Clin. Oncol. 2002; 21: 31a, (abstr)
   Google Scholar
• Geiger J., Hutchinson R., Hohenkirk L. F., McKenna E., Chang A., Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000; 356: 1163–1165
   PubMed Web of Science ®Google Scholar
• Geiger J. D., Hutchinson R. J., Hohenkirk L. F., McKenna E. A., Yanik G. A., Levine J. E., Chang A. E., Braun T. M., Mule J. J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61: 8513–8519
   PubMed Web of Science ®Google Scholar
• Schott M., Feldkamp J., Lettmann M., Simon D., Scherbaum W. A., Seissler J. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin. Endocrin. 2001; 55: 271–277
   PubMed Web of Science ®Google Scholar
• Gjertsen M. K., Bakka A., Breivik J., Saeterdal I., Gedde-Dahl T., 3rd, Stokke K. T., Solheim B. G., Egge T. S., Soreide O., Thorsby E., Gaudernack G. Ex vivo peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer 1996; 65: 450–453
   PubMed Web of Science ®Google Scholar
• Schott M., Feldkamp J., Schattenberg D., Krueger T., Dotzenrath C., Seissler J., Scherbaum W. A. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur. J. Endocrinol. 2000; 142: 300–306
   PubMed Web of Science ®Google Scholar
• Burch P. A., Breen J. K., Buckner J. C., Gastineau D. A., Kaur J. A., Padley D. J., Peshwa M. V., Pitot H. C., Richardson R. L., Smits B. J., Sopapan P., Strang G., Valone F. H., Vuk-Pavlovic S. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 2000; 6: 2175–2182
   PubMed Web of Science ®Google Scholar
• Fong L., Brockstedt D., Benike C., Wu L., Engleman E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 2001; 166: 4254–4259
   PubMed Web of Science ®Google Scholar
• Fong L., Brockstedt D., Benike C., Breen J. K., Strang G., Ruegg C. L., Engleman E. G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 2001; 167: 7150–7156
   PubMed Web of Science ®Google Scholar
• Frohlich M. W., Small E. J., Bok R. A., Gulla S. P., Valone F. H., Harris K. A., Reese D. M. Immunotherapy with prostatic acid phosphatase-loaded dendritic cells (PROVENGE) in prostate cancer patients with serologic progression after definitive local therapy. Proc. Am. Soc. Clin. Oncol. 2001; 20: 188a, (abstr)
   Google Scholar
• Small E. J., Fratesu O., Reese D. M., Strang G., Laus R., Peshwa M. V., Valone F. H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000; 18: 3894–3903
   PubMed Web of Science ®Google Scholar
• Tjoa B. A., Elgamal A. A., Murphy G. P. Vaccine therapy for prostate cancer. Urol. Clin. North Am. 1999; 26: 365–374
   PubMed Web of Science ®Google Scholar
• Shankar G., Kelley H., Lodge A., Boynton A., Papandreou C., Logothetis C., Elgamal A.-A. Monitoring immune responses of prostate cancer patients vaccinated with prostate-specific membrane antigen (PSMA) protein-loaded dendritic cells (DC) in a phase I/II clinical trial. Proc. Am. Assoc. Cancer Res. 2001; 42: 26–27, (abstr)
   Google Scholar
• Shankar G., Kelley H., Samadzadeh L., Lodge A., Boynton A., Papandreou C., Logothetis C., Belldegrun A., Elgamal A. Induction of tumor-specific immune responses in hormone-refractory prostate cancer patients treated with DCVax™ Prostate in a phase I/II clinical trial. Proc. Am. Assoc. Cancer Res. 2002; 43: 144, (abstr)
   Google Scholar
• Assikis V. J., Elgamal A.-A., Tu S.-M., Daliani D., Pagliaro L., Logothetis C., Papandreou C. Immunotherapy for androgen independent prostate cancer: results of a phase I trial with a tumor vaccine of autologous dendritic cells loaded with r-PSMA (DCVax™-Prostate). Proc. Am. Assoc. Cancer Res. 2002; 43: 676, (abstr)
   Google Scholar
• Takaue Y., Tanosaki R., Tobisu K., Kakizoe T., Mizunuma Y., Kawai H. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015. Proc. Am. Soc. Clin. Oncol. 2002; 21: 18b, (abstr)
   Google Scholar
• Mansi J. L., Pandha H. S., John J., Hutchinson J., Kristeleit H., Dalgleish A. Dendritic cell immunotherapy for metastatic prostate cancer using cryopreserved dendritic cells pulsed with allogeneic tumour lysate: a phase I/II trial. Proc. Am. Soc. Clin. Oncol. 2002; 21: 17b, (abstr)
   Google Scholar
• Vieweg J. W., Coleman D., Maurice M., Yancey D., Dahm P., Naoe M., Gilboa E., Heiser A. Immunotherapy of prostate cancer using dendritic cells transfected with PSA RNA: results of a phase I trial. Proc. Am. Soc. Clin. Oncol. 2001; 20: 251a, (abstr)
   Google Scholar
• Heiser A., Coleman D., Dannull J., Yancey D., Maurice M. A., Lallas C. D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 2002; 109: 409–417
   PubMed Web of Science ®Google Scholar
• Heiser A., Su Z., Dannull J., Coleman D., Yancey D., Maurice M., Lallas C., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. W. Phase I clinical trial using dendritic cells transfected with PSA RNA for immunotherapy of prostate cancer patients. Proc. Am. Assoc. Cancer Res. 2002; 43: 976, (abstr)
   Google Scholar
• Hinkel A., Gitlitz B., Mulders P., Moldawer N., Tso C., Kaboo R., Belldegrun A., Figlin R. Dendritic cell (DC) therapy for metastatic renal cell carcinoma (mRCC)—a translational phase I clinical trial. Proc. Am. Soc. Clin. Oncol. 1998; 17: 432a, (abstr)
   Google Scholar
• Marten A., Renoth S., Heinicke T., von Lilienfeld-Toal M., Schmidt-Wolf I. G.H. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a first clinical phase I/II trial in patients with metastatic renal cell carcinoma. Blood 2001; 98: 40a, (abstr)
   Google Scholar
• Kugler A., Stuhler G., Walden P., Zoller G., Zobywalski A., Brossart P., Trefzer U., Ullrich S., Muller C. A., Becker V., Gross A. J., Hemmerlein B., Kanz L., Muller G. A., Ringert R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 2000; 6: 332–336
   PubMed Web of Science ®Google Scholar
• Schott M., Seissler J., Lettmann M., Fouxon V., Scherbaum W. A., Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 2001; 86: 4965–4969
   PubMed Web of Science ®Google Scholar
• Schellhammer P., Small E. J., Higano C. S., Neumunaitis J., Peshwa M., Jones L., Strang G., Valone F. H. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double blind, placebo controlled trial. Proc. Am. Soc. Clin. Oncol. 2002; 21: 183a, (abstr)
   Google Scholar